Naohiro Okano

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto et al. · Journal of Clinical Oncology · 2022 · 103 citations

Immunology, Pathology, Aggressive Tumor Biology +21

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 85 citations · Full text

Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study.

Junji Furuse, Masafumi Ikeda, Makoto Ueno et al. · Journal of Clinical Oncology · 2023 · 22 citations

Placebo-controlled Phase 2, Pathology, Pharmacotherapy +16

Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao et al. · British Journal of Cancer · 2023 · 10 citations · Full text